Charles Schwab Investment Management Inc Clearside Biomedical, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 20,216 shares of CLSD stock, worth $23,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,216
Previous 20,216
-0.0%
Holding current value
$23,450
Previous $30,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CLSD
# of Institutions
53Shares Held
13.4MCall Options Held
17.6KPut Options Held
100-
Vanguard Group Inc Valley Forge, PA2.84MShares$3.29 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.55 Million3.43% of portfolio
-
Armistice Capital, LLC New York, NY2.14MShares$2.48 Million0.04% of portfolio
-
Carmignac Gestion Paris, I02.13MShares$2.47 Million0.05% of portfolio
-
Black Rock Inc. New York, NY798KShares$925,8380.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $69.8M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...